Phillip Beck represents a wide range of clients in intellectual property disputes across multiple venues, including before district courts, the Patent Trial and Appeal Board, the U.S. International Trade Commission, and the Court of Appeals for the Federal Circuit.
Phillip was part of a trial team that won a patent infringement case brought under the Biologics Price Competition and Innovation Act (BPCIA) related to one of the first, and most successful, biologic drugs. He has represented pharmaceutical and consumer electronics companies in inter partes reviews (IPRs) and in appeals to the Federal Circuit. Phillip has also represented a major consumer electronics company in FRAND (fair, reasonable, and non-discriminatory) litigation.
As an undergraduate student at Brigham Young University, Phillip spent two years as a histologist in an on-campus research lab investigating the biomolecular etiology and pathophysiology of osteoarthritis, using murine genetic and surgical osteoarthritis models.
Phillip is a member of the San Diego Intellectual Property Law Association.
The following represents experience acquired prior to joining Jones Day.
Represented a major pharmaceutical company in district court litigation brought under BPCIA related to one of the first, and most successful, antibody-related therapeutics. Served on the trial team that won judgment of infringement and validity.
Represented a major pharmaceutical company in prelitigation diligence of patent portfolio related to antibodies that modulate an immune checkpoint inhibitor as an oncological therapeutic.
Represented a pharmaceutical company in prelitigation diligence of patent portfolio related to third-generation (two co-stimulatory domain) CAR-T immuno-oncological therapeutic.
Represented a major memory semiconductor manufacturer and supplier in appeals from Patent Trial and Appeal Board inter partes review proceedings to the Court of Appeals for the Federal Circuit.
Represented a major pharmaceutical company in inter partes review proceedings related to small molecule HIV infection treatments.
Represented a major pharmaceutical company in inter partes review proceedings defending validity of patent related to techniques for improving the expression of antibodies.
Represented a major pharmaceutical company in prelitigation diligence of patent portfolio related to antibody/small molecule combination therapy for HIV infection.
- The George Washington University (J.D. cum laude 2017; Editorial Staff, AIPLA Quarterly Journal; Member, Moot Court Board; First Place, Rothwell Figg Intellectual Property Moot Court Competition); Brigham Young University (B.S. in Physiology and Developmental Biology 2012)
- California and District of Columbia
- Intern to Judge Kathleen O'Malley, U.S. Court of Appeals, Federal Circuit (Fall 2016)